Ironwood Pharmaceuticals (IRWD) said Monday that data from a phase 3 trial assessing apraglutide in adults with short bowel syndrome with intestinal failure showed a "consistent treatment effect."
The consistent effect was seen "across subgroups: gender, age, body weight, region, race, ethnicity and [short bowel syndrome characteristics] -- including length of remnant bowel," the company said.
The rare disease affects an estimated 18,000 adults in the US, Europe and Japan, Ironwood said.
The company said it's working to file a new drug application to the US Food and Drug Administration and marketing applications to other regulators for apraglutide to treat adults with the disease.
Ironwood shares were rising past 6% in recent trading.
Price: 4.07, Change: +0.11, Percent Change: +2.65
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.